Endocytic Trafficking Routes of Wild Type and ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator
-
Published:2004-06
Issue:6
Volume:15
Page:2684-2696
-
ISSN:1059-1524
-
Container-title:Molecular Biology of the Cell
-
language:en
-
Short-container-title:MBoC
Author:
Gentzsch Martina1, Chang Xiu-Bao1, Cui Liying1, Wu Yufeng1, Ozols Victor V.1, Choudhury Amit2, Pagano Richard E.2, Riordan John R.1
Affiliation:
1. Mayo Clinic College of Medicine, S.C. Johnson Medical Research Center, Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, Arizona 85259 2. Mayo Clinic College of Medicine, Department of Biochemistry and Molecular Biology and Thoracic Diseases Research Unit, Mayo Clinic, Rochester, Minnesota 55905
Abstract
Intracellular trafficking of cystic fibrosis transmembrane conductance regulator (CFTR) is a focus of attention because it is defective in most patients with cystic fibrosis. ΔF508 CFTR, which does not mature conformationally, normally does not exit the endoplasmic reticulum, but if induced to do so at reduced temperature is short-lived at the surface. We used external epitope-tagged constructs to elucidate the itinerary and kinetics of wild type and ΔF508 CFTR in the endocytic pathway and visualized movement of CFTR from the surface to intracellular compartments. Modulation of different endocytic steps with low temperature (16°C) block, protease inhibitors, and overexpression of wild type and mutant Rab GTPases revealed that surface CFTR enters several different routes, including a Rab5-dependent initial step to early endosomes, then either Rab11-dependent recycling back to the surface or Rab7-regulated movement to late endosomes or alternatively Rab9-mediated transit to the trans-Golgi network. Without any of these modulations ΔF508 CFTR rapidly disappears from and does not return to the cell surface, confirming that its altered structure is detected in the distal as well as proximal secretory pathway. Importantly, however, the mutant protein can be rescued at the plasma membrane by Rab11 overexpression, proteasome inhibitors, or inhibition of Rab5-dependent endocytosis.
Publisher
American Society for Cell Biology (ASCB)
Subject
Cell Biology,Molecular Biology
Reference58 articles.
1. Benharouga, M., Haardt, M., Kartner, N., and Lukacs, G.L. (2001). COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments.J. Cell Biol.153, 957-970. 2. Bonifacino, J.S., and Traub, L.M. (2003). Signals for sorting of transmembrane proteins to endosomes and lysosomes.Annu. Rev. Biochem.72, 395-447. 3. Bradbury, N.A., Clark, J.A., Watkins, S.C., Widnell, C.C., Smith, H.S.T., and Bridges, R.J. (1999). Characterization of the internalization pathways for the cystic fibrosis transmembrane conductance regulator.Am. J. Physiol.276, L659-L668. 4. Bradbury, N.A., Jilling, T., Berta, G., Sorscher, E.J., Bridges, R.J., and Kirk, K.L. (1992). Regulation of plasma membrane recycling by CFTR.Science256, 530-532. 5. Brown, C.R., Hong-Brown, L.Q., and Welch, W.J. (1997). Strategies for correcting the delta F508 CFTR protein-folding defect.J. Bioenerg. Biomembr.29, 491-502.
Cited by
184 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|